Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)-Reference-Cited by-同舟云学术

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Published:2020-10-03 Issue:3 Volume:22 Page:373-387
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Nakamura Ichiro¹,Maegawa Hiroshi²,Tobe Kazuyuki³,Uno Satoshi⁴

Affiliation:

1. Operational Excellence, Medical Affairs Japan, Astellas Pharma Inc., Tokyo, Japan

2. Department of Medicine, Shiga University of Medical Science, Shiga, Japan

3. First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan

4. Data Science, Development, Astellas Pharma Inc., Tokyo, Japan

Funder

Astellas Pharma Inc

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1817388

Reference54 articles.

1. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

2. Current understanding of the effect of sodium–glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus

3. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

4. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice;Journal of Diabetes Investigation;2024-08-14

2. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis;Journal of the American Pharmacists Association;2024-01

3. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

4. Aspects of the safety of hypoglycemic drugs according to the results of clinical trials;Patient-Oriented Medicine and Pharmacy;2023-06-07

5. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study;Expert Opinion on Drug Safety;2023-05-29